Phenotypic detection of Extended Spectrum Beta-Lactamases and Amp C Beta- Lactamases among nosocomial isolates in a tertiary care hospital

Abstract

Background & objectives: Extended-Spectrum Beta-Lactamases (ESBLs) is an important resistance mechanism in Enterobacteriaceae infections. Lack of standard guidelines from Clinical Laboratory Standards Institute (CLSI) for Amp C beta-lactamase detection poses a problem. This study was undertaken to detect ESBLs by phenotypic tests and Amp C beta-lactamase by inhibitor based method. Material and Methods: 200 consecutive non-repetitive isolates of E.coli, Klebsiella and Proteus from clinical samples were screened for ESBLs as per CLSI guidelines and confirmed by PCDT, DDST and E-tests (AB Biodisk, Biomerieux). Amp C beta lactamases were screened by cefoxitin resistance and confirmed by inhibitor (Cloxacillin) based method. Simultaneous occurrence of Amp C and ESBLs was detected by combined disk test (Neo-Sensitabs and Diatabs). Descriptive and Kappa statistics were used. Results: Out of 200 isolates studied, 131 were initially screened as ESBL producers and later 114 (57%) were confirmed by phenotypic methods. E-Test was found most sensitive phenotypic test as compared to PCDT and DDST. 13 strains resistant to cefoxitin (30µg) were found to be pure Amp C producers. Combined disk test detected 36 to be ESBL and Amp C co-producers. Surprisingly, six isolates found sensitive to cefoxitin disk were confirmed as Amp C producers by cloxacillin disk inhibition test. Conclusion: 57% ESBLs and 27.5% Amp C producers were isolated from nosocomial pathogens showing significant resistance to 3rd generation cephalosporins. Phenotypic confirmation by E-test, PCDT & DDST were useful for ESBL identification and for detection of Amp C, cloxacillin was found to be an effective inhibitor.

Polymicrobial Septic Shock with Multiorgan Dysfunction in an Otherwise Healthy Immunocompetent Patient

“…Polymicrobial sepsis with co-infective emerging bacterial and viral pathogens can cause severe disease which is worsened by healthcare-associated infections thereby obfuscating the clinical presentation and creating caveats to optimal diagnosis and treatment. [5][6][7][8][9][10] Lipopolysaccharide, lipid A and endotoxin from Gram-negative pathogens, lipoteichoic acid from Grampositive pathogens, components from fungi, parasites and viruses stimulate. Toll-like receptor-mediated signaling leading to activation of NF-kb within monocytes.…”

Emerging Antimicrobial Resistance and Evolving Healthcare: Dangerous Crossroads for the Community and the Military

“…Secondly, natural evolution of microorganisms confers an increase in virulence, stability, transmissibility, infectivity, pathogenicity, and antimicrobial resistance. Organisms not known to be pathogenic earlier are now being encountered as opportunistic pathogens (1,(11)(12)(13). Established pathogens are evolving into potentially untreatable multiresistant mutants such as methicillin resistant Staphylococcus aureus (MRSA), Methicillin Resistant Coagulase negative Staphylococcus (MR-CONS), Vancomycin Resistant Staphylococcus aureus (VRSA), vancomycin resistant Enterococci (VRE), Extended Spectrum Beta Lactamase (ESBL) Gram negative bacteria, Carbapenem Resistant Enterobacteriaceae (CRE), and pan drug resistant (PDR) gram negative bacteria, which are resistant to all available antimicrobials.…”

Panresistant Superbugs: Are We at the Edge of a ‘Microbial Holocaust’

“…World Health Organization (WHO) theme for World Health Day 2011 was PUBLIC HEALTH AND EPIDEMIOLOGY "Antimicrobial resistance: No action today, no cure tomorrow" [2]. Since then, despite progressive steps towards concept development, the magnitude of panresistance overshadows control efforts [3,4]. Panresistance is a complete roadblock to years of progress made towards advanced healthcare.…”